- Home
- TT vs SNY Comparison
TT vs SNY Comparison
Compare TT & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TT | SNY |
|---|---|---|
| Founded | 1885 | 1994 |
| Country | Ireland | France |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.8B | 104.5B |
| IPO Year | 2009 | 2001 |
Fundamental Metrics
Financial Performance| Metric | TT | SNY |
|---|---|---|
| Price | $447.47 | $44.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $489.38 | $58.00 |
| AVG Volume (30 Days) | 770.0K | ★ 2.3M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | 0.88% | ★ 3.47% |
| EPS Growth | ★ 15.48 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $14,782,000,000.00 | N/A |
| Revenue This Year | $12.12 | $3.49 |
| Revenue Next Year | $8.06 | $6.10 |
| P/E Ratio | $65.72 | ★ $6.14 |
| Revenue Growth | ★ 5.58 | N/A |
| 52 Week Low | $348.06 | $40.89 |
| 52 Week High | $505.87 | $52.68 |
Technical Indicators
Market Signals| Indicator | TT | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 48.72 |
| Support Level | $440.06 | $43.28 |
| Resistance Level | $466.77 | $45.22 |
| Average True Range (ATR) | 9.09 | 0.62 |
| MACD | -1.95 | -0.13 |
| Stochastic Oscillator | 24.39 | 21.18 |
Price Performance
Historical ComparisonAbout TT Trane Technologies plc
Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for approximately 80% of its revenue, with 13% from EMEA and 7% Asia-Pacific. The company was formed in 2020 when its former parent, Ingersoll Rand, merged with Gardner Denver in a tax-advantaged reverse Morris trust transaction.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.